It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATEC’s FA Score shows that 0 FA rating(s) are green whileNVST’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATEC’s TA Score shows that 5 TA indicator(s) are bullish while NVST’s TA Score has 5 bullish TA indicator(s).
ATEC (@Medical Specialties) experienced а +40.83% price change this week, while NVST (@Medical Specialties) price change was -1.25% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.63%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -3.41%.
ATEC is expected to report earnings on Oct 30, 2025.
NVST is expected to report earnings on Oct 29, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
ATEC | NVST | ATEC / NVST | |
Capitalization | 1.9B | 3.67B | 52% |
EBITDA | -110.59M | 171M | -65% |
Gain YTD | 62.309 | 2.177 | 2,862% |
P/E Ratio | N/A | 21.74 | - |
Revenue | 482M | 2.57B | 19% |
Total Cash | 221M | 940M | 24% |
Total Debt | 542M | 1.65B | 33% |
ATEC | NVST | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 52 | 100 | |
SMR RATING 1..100 | 100 | 89 | |
PRICE GROWTH RATING 1..100 | 37 | 50 | |
P/E GROWTH RATING 1..100 | 100 | 61 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (78) in the null industry is in the same range as ATEC (99) in the Medical Specialties industry. This means that NVST’s stock grew similarly to ATEC’s over the last 12 months.
ATEC's Profit vs Risk Rating (52) in the Medical Specialties industry is somewhat better than the same rating for NVST (100) in the null industry. This means that ATEC’s stock grew somewhat faster than NVST’s over the last 12 months.
NVST's SMR Rating (89) in the null industry is in the same range as ATEC (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to ATEC’s over the last 12 months.
ATEC's Price Growth Rating (37) in the Medical Specialties industry is in the same range as NVST (50) in the null industry. This means that ATEC’s stock grew similarly to NVST’s over the last 12 months.
NVST's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for ATEC (100) in the Medical Specialties industry. This means that NVST’s stock grew somewhat faster than ATEC’s over the last 12 months.
ATEC | NVST | |
---|---|---|
RSI ODDS (%) | 1 day ago85% | 2 days ago56% |
Stochastic ODDS (%) | 1 day ago86% | 2 days ago74% |
Momentum ODDS (%) | 1 day ago85% | 2 days ago66% |
MACD ODDS (%) | 1 day ago84% | 2 days ago61% |
TrendWeek ODDS (%) | 1 day ago83% | 2 days ago70% |
TrendMonth ODDS (%) | 1 day ago83% | 2 days ago71% |
Advances ODDS (%) | 3 days ago85% | 14 days ago67% |
Declines ODDS (%) | 1 day ago82% | 2 days ago69% |
BollingerBands ODDS (%) | 1 day ago90% | 2 days ago64% |
Aroon ODDS (%) | N/A | 2 days ago72% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FTADX | 55.92 | N/A | N/A |
Fidelity Advisor International Discv M | |||
HWSIX | 73.07 | N/A | N/A |
Hotchkis & Wiley Small Cap Value I | |||
NMUCX | 10.31 | N/A | N/A |
Neuberger Berman Multi-Cap Opp C | |||
FGKMX | 133.58 | N/A | N/A |
Fidelity Advisor Communication ServicesZ | |||
FEMAX | 11.67 | N/A | N/A |
First Eagle U.S. SMID Cap Opportunity A |
A.I.dvisor indicates that over the last year, NVST has been loosely correlated with BIO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NVST jumps, then BIO could also see price increases.
Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
---|---|---|---|---|
NVST | 100% | -1.79% | ||
BIO - NVST | 57% Loosely correlated | -2.89% | ||
A - NVST | 55% Loosely correlated | -1.44% | ||
XRAY - NVST | 54% Loosely correlated | -2.63% | ||
ALGN - NVST | 53% Loosely correlated | -1.97% | ||
MTD - NVST | 53% Loosely correlated | -1.78% | ||
More |